Amylyx Overview
- Founded
- 2013
- Status
- Private
- Employees
- 3
- Latest Deal Type
- Series B
- Latest Deal Amount
- $59.6M
- Investors
- 6
Amylyx General Information
Description
Developer of a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases designed to target the neuroinflammation and nerve cell death that characterize these disorders. The company's therapeutics are a combination of existing compounds that have synergistic effects in preventing nerve cell death and neurotoxic inflammation in multiple preclinical models, enabling patients suffering from Alzheimer's disease and other neuroinflammation diseases to begin treatment more quickly, resulting in a higher likelihood of successful treatment.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 43 Thorndike Street
- Cambridge, MA 02141
- United States
+1 (617) 000-0000
Amylyx Timeline
Amylyx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series B) | 01-Jul-2020 | $59.6M | 000.00 | Completed | Generating Revenue | |
| 4. Debt - PPP | 13-Apr-2020 | 00.00 | Completed | Startup | ||
| 3. Early Stage VC (Series A) | 22-Aug-2016 | 000 | 00.00 | 0000 | Completed | Startup |
| 2. Grant | 20-Jul-2016 | $3.56M | $1.3M | Completed | Startup | |
| 1. Early Stage VC | $1.3M | $1.3M | Completed | Startup |
Amylyx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Amylyx Executive Team (8)
Amylyx Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alan Walts Ph.D | Self | Board Observer | 000 0000 |
| Felix von Coerper | ALS Investment Fund | Board Member | 000 0000 |
| George Milne | Amylyx | Board Member | 000 0000 |
| Isaac Cheng MD | Morningside Group | Board Member | 000 0000 |
| Joshua Cohen | Amylyx | Co-Founder, Co-Chief Executive Officer & Chairman | 000 0000 |
Amylyx Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAmylyx Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| ALS Investment Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Henri Termeer | Angel (individual) | Minority | 000 0000 | 000000 0 | |
| Morningside Group | Venture Capital | Minority | 000 0000 | 000000 0 | |
| ALS Finding a Cure Foundation | Limited Partner | Minority | 000 0000 | 000000 0 | |
| Cure Alzheimer's Fund | Angel (individual) | Minority | 000 0000 | 000000 0 |